Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001104659-25-115063·Acrivon Therapeutics, Inc.
Schedule 13G ownership disclosure
ACRIVON THERAPEUTICS INC
Common Stock, par value $0.001 per share (the "Shares") · CUSIP: 004890109
Event date: 2025-11-14
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Citadel Advisors LLC
Shares: 1,541,326.00 · Class: 4.9%
- Citadel Advisors Holdings LP
Shares: 1,541,326.00 · Class: 4.9%
- Citadel GP LLC
Shares: 1,541,326.00 · Class: 4.9%
- Citadel Securities LLC
Shares: 180,541.00 · Class: 0.6%
- Citadel Securities Group LP
Shares: 180,541.00 · Class: 0.6%
- Citadel Securities GP LLC
Shares: 180,541.00 · Class: 0.6%
- Kenneth Griffin
Shares: 1,721,867.00 · Class: 5.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-115063
- Form type
- SCHEDULE 13G
- Filer
- Acrivon Therapeutics, Inc.
- CIK
- CIK 1781174
- Filed
- Nov 21, 2025
- Reporting period
- Nov 14, 2025
- Description
- Schedule 13G beneficial ownership